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Background & aims: Probiotics is an emerging therapeutic agent which may alleviate the symptoms of
constipation. We evaluated the effectiveness of microbial cell preparation (Hexbio) containing fruc-
tooligosaccharide, Biﬁdobacterium and Lactobacillus in improving stool frequency and symptoms of
chronic constipation.
Methods: A total of 120 constipated adults diagnosed using Rome III criteria were randomized and given
either microbial cell preparation or placebo to be consumed twice daily. Follow-up was done after a
7-day intervention based on a questionnaire which includes an assessment of symptom proﬁle and a
stool diary.
Results: During the intervention period, the stool frequency was higher (p ¼ 0.001) in the treatment
group. Subjects experienced less straining (p ¼ 0.001) and sensation of incomplete evacuation
(p < 0.001), as well as improved stool consistency (p < 0.001) compared to the placebo group. While a
higher proportion of subjects in the treatment group had a reduction in anorectal blockage sensation and
having to defecate by manual maneuvers, the differences were not statistically signiﬁcant.
Conclusion: The results suggest that microbial cell preparation is effective in improving stool frequency
and stool consistency. Furthermore, it could reduce the symptoms of straining and sensation of
incomplete evacuation in adults with chronic functional constipation.
MREC Reg. No.: 866.59 (IRB, UMMC, Malaysia).
 2013 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism.
Open access under CC BY-NC-ND license.1. Introduction
Constipation is characterized by difﬁculty in defecation, with
dry and hard stools and infrequent defecation of less than three
times per week. It is a fairly common condition as recent epide-
miological data showed that prevalence of constipation in North
America is 3.2e45% (median 16%), Europe 0.7e79% (median 19.2%)
and Asia 1.4e32.9% (median 10.8%).1 The incidence of adult con-
stipation increases after the age of 60 and is more predominant in
females.1 The cause of chronic constipation can be multifactorial
and the exact pathophysiology is often elusive.2 Underlying risk
factors are low ﬁber diet, low water intake, low physical activity,
laxative abuse and lifestyle changes.3,4 Constipation has also been
linked with abnormal fecal ﬂora, such as decreased concentrationsBiannual Congress of Paren-
A) in Penang, Malaysia 2012.
ram).
for Clinical Nutrition and Metabolof lactic acid bacteria and increased methanogens, potentially
pathogenic bacteria and fungi.5
Functional constipation is diagnosed when no underlying
organic cause can be identiﬁed.6 When constipation is prolonged, it
can lead to complications like hemorrhoids, anal ﬁssures and rectal
bleeding. Although non life-threatening, chronic constipation has a
signiﬁcant impact on the quality of life, hence the management of
the symptoms is important in improving quality of life for the
patients.7
The best treatment for constipation relies on a clear under-
standing of the underlying cause, although it is not often found.
Changes in lifestyle and dietary habits are usually recommended,
for example increasing the intake of ﬁber and ﬂuid. Besides dietary
and lifestyle changes, the standard medication for constipation is
laxatives.8 Recently, other therapeutic options in treating chronic
constipation have been investigated. A fairly new approach to treat
constipation is the consumption of probiotics and prebiotics. Pro-
biotics are deﬁned as microbial cell preparations or components of
microbes that have a beneﬁcial effect on the health and well-being
of the host.9 Probiotic bacteria such as Lactobacillus andism. Open access under CC BY-NC-ND license.
Fig. 1. CONSORT diagram of patient recruitment and analysis.
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acetic acid which can lower the pH of the colon, enhancing peri-
stalsis and reducing colonic transit time.10 Prebiotics are certain
types of soluble ﬁbers for example fructooligosaccharides (FOS),
galactooligosaccharides (GOS) and inulin that promote the growth
and activity of probiotic bacteria in the colon.
This study was carried out to evaluate the effects of a microbial
cell preparation (Hexbio) containing FOS, Biﬁdobacterium and
Lactobacillus on stool frequency, stool consistency and symptoms of
chronic constipation in adults.
2. Materials & methods
2.1. Subjects
Subjects were recruited from the primary day care clinic, med-
ical clinic or surgical clinic at University of Malaya Medical Centre,
Malaysia. A total of 132 subjects, aged 18 and above, were screened
based on the Rome III diagnostic criteria for having chronic con-
stipation (Table 1).11 Subjects with irritable bowel syndrome (IBS)
or organic constipation (constipation associated with any
neoplastic diseases, neuropathy or mechanical obstructions), se-
vere medical complications such as end-stage renal failure, liver
cirrhosis, malignancy, chronic congestive heart failure and long
term laxative users were excluded. Out of this cohort of patients,
120 subjects were included in the trial (Fig. 1). The protocol was
approved by the Institutional Review Board (IRB) of the University
Malaya Medical Centre (Reference no: 866.59). The study was
explained to all recruited subjects by the clinical researchers and
written informed consent was obtained before enrolment into the
trial.
2.2. Study design
Subjects were randomized using the sealed envelope method to
either the treatment or placebo group. They were given sachets
containing either microbial cell preparation or placebo to be
consumed twice daily for 7 consecutive days. The treatment sample
consisted of an orange ﬂavored, granulated microbial cell prepa-
ration (Hexbio), containing Lactobacillus acidophilus, Lactobacillus
casei, Lactobacillus lactis, Biﬁdobacterium biﬁdum, Biﬁdobacterium
longum and Biﬁdobacterium infantis with 3  1010 colony forming
units (cfu) per sachet. The composition includes the strains listed
above, granulated fermented milk, lactose, fructooligosaccharide
and ﬂavouring. The placebo sample was similar in appearance and
composition but it was not fermented and contained no FOS and
microbial cells. Nutritional compositions are crude protein (0.16 g/
sachet), crude fat (0), crude ﬁber (0), carbohydrate (2.7 g/sachet)
and calories (11.6 kcal/sachet). Hexbio is a granulated formulationTable 1
Rome III diagnostic criteria for functional constipation.
Symptoms of functional constipation
Symptomatic for the last 3 months
Onset 6 months prior to diagnosis
2 of following symptoms
- Straining
- Lumpy/hard stools
- Incomplete evacuation
- Anorectal blockage
- Manual maneuvers to aid in defecation
- < 3 Smooth bowel movements per week
Loose stools rarely present without laxatives
Insufﬁcient criteria for IBSfor oral consumption. Patients and researchers were blinded to the
allocated groups and the treatment allocation was revealed at the
end of the research, once analysis was done.
The subjects were advised to continue their normal diet but
avoid any other probiotic products, laxatives or ﬁber supplements
during the study period. For baseline assessment, a medical history,
demographic details, information on the current defecation pattern
and constipation symptoms were recorded. Follow-up was done at
the end of the study period based on a questionnaire which in-
cludes symptomatic improvement and a stool diary.2.3. Outcome evaluation
The primary outcome measured was frequency of bowel
movements per week. The secondary outcomes measured were the
self perception on the improvement of symptoms (straining, lumpy
or hard stool, sensation of incomplete evacuation, sensation of
anorectal blockage and manual maneuvers to aid in defecation)
after the 1 week treatment period.2.4. Sample size
Sample size was calculated based on the stool frequency stan-
dard difference of 0.66 between the two groups.12 Therefore, a total
sample size of 120 (60 in each group) with 1:1 allocation was
determined to be sufﬁcient to expect 95% power with a 5% signif-
icance level and 10% attrition rate.
Fig. 2. Stool frequency of placebo and treatment groups before and after intervention.
Boxplots show 25th and 75th percentiles, median and range. *p ¼ 0.001 signiﬁcantly
different from the placebo group using Kruskal Wallis test.
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Analysis was performed using SPSS V.16.0 statistical software
based on the intention-to-treat (ITT) principle. Differences between
the two treatment groups at baseline were evaluated using Manne
Whitney and Chi-square tests. Comparison of stool frequency
before and after interventionwas done using the KruskalWallis test
and improvement of symptoms was assessed using the Chi-square
test. Results with a p-value of <0.05 was considered statistically
signiﬁcant.
3. Results
3.1. Baseline characteristics
Between March 2011 and December 2011, a total of 120 subjects
were recruited but 12 did not complete the study and were
considered dropouts. Dropouts were due to loss to follow-up,
consent withdrawal and non compliance such as consuming <
80% of the test samples, intake of antibiotics, laxatives or other
probiotics during the treatment period. Table 2 shows the baseline
characteristics for the two groups (treatment and placebo). Overall,
the majority of subjects recruited were females (62%) compared to
males (38%). On average, the subjects have been suffering from
constipation for 1 year or more and showed 3 or more symptoms
for constipation. The median ages were 41.5 and 37 years for
treatment and placebo groups respectively. There were no signiﬁ-
cant differences between the two groups in terms of age, gender,
ethnic origin, duration of constipation, stool frequency and symp-
toms. Furthermore, history of abdominal surgery, alcohol con-
sumption, smoking and exercisewere also comparable between the
two groups. This illustrates that both groups were well randomized
and unbiased at baseline.Table 2
Baseline characteristics of treatment vs placebo groups.
Baseline characteristics Treatment Placebo p Value
Number of subjects (n) 50 58
Age, median (range) 41.5 (18e81) 37 (20e78) 0.890a
Gender, n (%)
Male 17 (34) 24 (41.4) 0.431
Female 33 (66) 34 (58.6)
Ethnic origin, n (%)
Malay 25 (50) 30 (51.7) 0.592
Chinese 14 (28) 15 (25.9)
Indian 11(22) 11(19)
Others 0 (0) 2 (3.4)
Years of constipation, median
(range)
2.0 (0.5e10) 1.0 (0.25e30) 0.644a
Stool frequency, median (range) 3 (0.5e7) 3 (0.5e7) 0.352a
Constipation symptoms, n (%):
Straining 37 (74) 46 (79.3) 0.648
Lumpy or hard stool 44 (88) 54 (93.1) 0.509
Sensation of incomplete evacuation 42 (84) 43 (74.1) 0.245
Sensation of anorectal blockage 19 (38) 18 (31) 0.543
Manual maneuvres to aid in
defecation
8 (16) 9 (15.5) 1.000
< 3 Times defecation per week 21 (42) 19 (32.8) 0.424
History of abdominal surgery, n (%) 13 (26) 10 (17.2) 0.268
Alcohol consumer, n (%) 7 (14) 8 (13.8) 0.975
Smoker, n (%) 2 (4) 8 (13.8) 0.080
Regular exercise, n (%) 18 (36) 21 (36.2) 0.982
Unless indicated, other p-values are obtained using Chi-square test.
a p-Value obtained using ManneWhitney Test.3.2. Stool frequency
At baseline, the median defecation frequency for the placebo
and treatment groups were both 3 (0.5e7) times/week. There was
no signiﬁcant difference in the stool frequency before intervention
in the placebo and treatment groups. During the 7 days interven-
tion, the stool frequency of the treatment group increased to 6 (1e
13) while the placebo group was 4 (1e10). Therefore, with inter-
vention, stool frequency in the treatment group was signiﬁcantly
higher (p ¼ 0.001) than the placebo group as shown in Fig. 2.
3.3. Constipation symptoms
Improvement of constipation symptoms is shown in Table 3. In
the treatment group, subjects experiencing less straining during
the intervention period was 66.7% compared to 29.8% for the pla-
cebo group. Additionally, subjects in the treatment group reported
a signiﬁcant decrease in lumpy hard stools (66.7% vs 29.8%) and
sensation of incomplete evacuation (75.6% vs 31.4%) as compared to
the placebo. A higher proportion of subjects in the treatment group
felt that there was an improvement of anorectal blockage sensation
(66.7% vs 39.1%) and reduction in having to defecate by manual
maneuvers (77.8% vs 46.7%). However, the differences were notTable 3
Improvement of constipation symptoms in the treatment vs placebo groups.
Symptoms Treatment Placebo p
% with Improvement
Straining 66.7 29.8 0.001
Lumpy hard stools 82.9 31.4 <0.001
Sensation of incomplete evacuation 75.6 27.9 <0.001
Sensation of anorectal blockage 66.7 39.1 0.068
Manual maneuvers to defecate 77.8 46.7 0.134
p-Value obtained using Chi-square test.
S. Jayasimhan et al. / Clinical Nutrition 32 (2013) 928e934 931statistically signiﬁcant. No adverse effects were reported in this
study.
4. Discussion
The presence of probiotics plays an important role in main-
taining a healthy balance in the intestine. Studies have shown that
there are differences in the intestinal microbiota between healthy
persons and patients with chronic constipation.13 Patients with
chronic constipation have lower concentrations of intestinal Biﬁ-
dobacterium and Lactobacillus and higher pathogenic bacteria and
fungi.5,14 Whether this imbalanced microbiota is a factor contrib-
uting to constipation or a manifestation of constipation is un-
known. This observation may justify the use of probiotics as a
therapeutic agent in treating chronic constipation.
Hexbio is a fermented milk product in granule form with FOS
and a mixed culture of six strains of Lactobacillus and Biﬁdo-
bacterium. This combination is used as Lactobacillus tends to
colonize the small intestine while Biﬁdobacterium are found pre-
dominantly in the colon.15,16 Additionally, the presence of FOS
may encourage the growth of probiotics in the colon. In this study,
there may be a variation in the consumption of diet despite our
instruction of taking a normal diet, which was not standardized by
our dietician. Nevertheless, as the two groups in this randomized
trial are well matched at baseline, we anticipate that this con-
founding effect has been effectively resolved by the process of
randomization. During the one week intervention period, the
stool frequency of the treatment group increased signiﬁcantly
compared to the placebo group (p ¼ 0.001). This demonstrates the
efﬁcacy of a microbial cell preparation containing Biﬁdobacterium
and Lactobacillus on increasing the frequency of bowel move-
ments per week. The production of short-chain fatty acids such as
acetate, propionate and butyrate by Biﬁdobacterium and Lactoba-
cillus may result in a lower pH in the colon. A lower pH improves
the intestinal peristalsis which eventually leads to a decrease in
the colonic transit time.10,17 A study by Krammer et al., 2011 on
patients with chronic constipation showed that consumption of
L. casei Shirota accelerated the colonic transit time and improved
defecation frequency.17
Subjects treated with Hexbio had a signiﬁcant improvement
in constipation symptoms such as straining, hard stools and
sensation of incomplete evacuation. It has been suggested that
probiotics soften the stools by increasing the secretion of water
and electrolytes.18 The fermentation process by probiotics in the
intestine produces short-chain fatty acids which promote os-
motic stimulation.19 Studies on healthy adults have shown an
increase in short-chain fatty acids and improvement in defeca-
tion conditions after the administration of probiotics.20,21 Softer
stools and an improved intestinal peristalsis will likely relieve
the symptoms of constipation as shown in our study. There was
improvement in the anorectal blockage sensation and reduction
in having to defecate by manual maneuvers in the treatment
group. However, when compared to the placebo group, the dif-
ferences were not statistically signiﬁcant. This could be due to
the smaller number of subjects having these two complaints at
baseline. A total of 37 (34.3%) subjects reported anorectal
blockage sensation and only 17 (15.7%) subjects had to use
manual maneuvers to aid in defecation. Furthermore, these two
symptoms could indicate a more severe spectrum of chronic
constipation and 7 days intervention might not be sufﬁcient for
any signiﬁcant changes.
Probiotics has been shown to be effective in increasing stool
frequency and improving symptoms in other studies as well.12,22
However, randomized controlled trials using probiotics were con-
ducted on different strains or single strain, hence a directcomparison is difﬁcult. In a pilot study involving constipated chil-
dren, a probiotics mixture containing Biﬁdobacterium and Lacto-
bacillus increased stool evacuations but did not show signiﬁcant
improvement in stool consistency.23 The authors suggested that a
larger sample size should be tested as only 35% of the children had
hard stools at baseline. Waitzberg et al. assessed the effects of FOS
and probiotics mixture of Lactobacillus and Biﬁdobacterium on
bowel movement frequency and constipation symptoms after a one
month intervention.24 They found an improvement in stool fre-
quency and consistency as well as constipation symptoms in the
treatment group.24 However, these effects were signiﬁcant after the
second and third weeks of treatment while our study showed
signiﬁcance after one week.24
Similarly, a study on constipated women showed improvement
in stool frequency, defecation condition and stool condition after
one week of consuming fermented milk containing Biﬁdobacterium
lactis.12 Althoughmost trials using probiotics showed some positive
results (Table 4), a multicentre trial conducted on children pro-
duced no signiﬁcant difference in constipation symptoms and stool
frequency in the probiotics B. lactis treatment group.25 These two
trials used a similar strain of B. lactis in fermented milk and had
comparable sample size but achieved opposing outcomes. The
different response seen could be due to the different study popu-
lation or scoring methods used. It is still unclear if multistrain
probiotics is better than single strain for treatment of constipation
as both have shown various degrees of effectiveness. However,
based on a review by Chapman et al., 2011 comparing the use of
multi or single strain probiotics for a range of health related out-
comes, it was suggested that multistrain mixtures show higher
efﬁcacy against vast a range of end points.26 This might be an effect
of synergistic interaction between the multistrains in the probiotic
mixtures.26 The presence of prebiotic, fermentation product and
other compositions in the treatment mixture might also affect the
results.
A recent review of the safety of Lactobacillus and Biﬁdobacte-
rium showed that there was no health damage and adverse effects
for the consumers.27 In accordance to this, there were no adverse
effects reported in our study. However, there are concerns about
the safety of probiotics in immunocompromised patients. Further
studies in this population are necessary to determine whether
probiotics are safe in these patients and could be used as a ther-
apeutic agent. Laxative is still the most commonly prescribed
medication for constipation although probiotics has gained
attention as an alternative treatment. Certain synthetic laxatives
like polyethylene glycol could alter colonic ﬂora by decreasing the
number of Biﬁdobacterium and short-chain fatty acids in the
stool.28 Therefore, probiotics can either be an adjunct to the
conventional use of laxatives or be given alone in the treatment of
constipation.
In this trial, we demonstrated that short-term intervention
with probiotics improved the symptoms of chronic constipation.
However, it may be important to evaluate the outcome after a
longer duration of treatment and whether or not these beneﬁcial
effects will be maintained after cessation of probiotics intake.
Although the constipation symptoms of the probiotics group
improved over the treatment period, analysis of the stool was not
carried out. The promising results from this trial warrant further
investigation such as analysis of stool pH and probiotics content in
order to determine the exact mechanism of action. Finally, it
would be interesting to study the potential protective effects of
long term probiotics consumption on prevention of colon cancer
as probiotics and prebiotics were proven to favourably alter
colorectal cancer biomarkers.29 Moreover, constipation and
infrequent bowel movements have been linked to a higher risk of
colon cancer.30
Table 4
(a) Studies using probiotics as treatment for constipation in adults. (b) Studies using probiotics as treatment for constipation in children.
Study ID Probiotic strains Design Constipation criteria Patients (N), age Duration Study outcomes (probiotic treatment group)
(a)
An et al., 201031 L. acidophilus (LH) CBT,
P. pentosaceus (PP) CBT
and B. longum SPM1205
Non-RCT, observational
study
Laxative usage >1
per week
Nursing home
residents (19)
Age: 77.1  10.1 years
2 Weeks Increase in stool frequency, amount of stool excreted and normal
stool during defecation, but changes NS.
Increase of fecal LAB levels (p < 0.05)
Decrease in harmful enzymes of intestinal microﬂora:
tryptophanase (p ¼ 0.047) and urease (p ¼ 0.005)
De Milliano
et al., 201232
B. biﬁdum W23, B. lactis
W52, B. longum W108,
L. casei W79, L. plantarum
W62 and L. rhamnosus W71
Non-RCT, observational
study
Rome III Pregnant women (20)
Age: 29.5  5.3 years
4 Weeks Decrease in: Straining during defecation (p ¼ 0.01),
hard stools (NS), sensation of incomplete evacuation (p < 0.01)
Sensation of anorectal obstruction (p < 0.01)
Manual maneuvres (NS)
Abdominal pain (p ¼ 0.01)
Reﬂux episodes (p ¼ 0.01)
Fateh et al., 201133 L. casei NCIMB1 30185,
L. rhamnosus NCIMB 30188,
S. thermophilus NCIMB 30189,
B. breve NCIMB 30180,
L. acidophilus NCIMB 30184,
B. longum NCIMB 30182,
L. bulgaricus NCIMB 30186
FOS
RCT, parallel,
placebo-controlled
Rome III Men (31 treatment :
29 control)
Age: >18 years
4 Weeks Stool frequency increased in the synbiotic compared with the
placebo group (p ¼ 0.02).
Improvement of Bristol stool form score (weeks 2 and 4
[p ¼ 0.006])
Laxative use and performing manual maneuvres (NS)
Patients perception that the treatment was effective or “partially
effective” was higher in the synbiotic group compared to the
placebo (p ¼ 0.037).
Koebnick
et al., 200322
L. casei Shirota RCT, parallel,
placebo-controlled
Patients with
chronic idiopathic
constipation
Adults (35 treatment:
35 control)
Age: 18e70 years
4 Weeks Decrease in moderate to severe constipation (p ¼ 0.001) and
hard and lumpy stools (p < 0.011) from week 2 onwards
Increase in stool frequency from week 2 (p < 0.001)
Occurrence of ﬂatulence and bloating (NS)
Riezzo et al., 201221 L. paracasei IMPC 2.1 RCT, crossover, artichoke
vs probiotic-enriched
artichoke
Rome III Adults (10 treatment:
10 control)
Age: 38.8  14.4 years
15 Days +
15 days
Preference: Probiotic-enriched artichokes (80%) vs ordinary
artichokes (20%)
Relief from constipation symptoms higher in probiotic-enriched
artichokes (p ¼ 0.0014)
Improvement of stool consistency (p ¼ 0.009)
Improvement in GSRS (Gastrointestinal Symptom Rating Scale)
constipation score (p ¼ 0.032)
Higher propionic acid levels in probiotic treatment group
(p ¼ 0.035)
Waitzberg
et al., 201224
L. paracasei (Lpc-37),
L. rhamnosus (HN001),
L. acidophilus (NCFM) and
B. lactis (HN019)
FOS
RCT, parallel,
placebo-controlled
Rome III Women (49 treatment:
50 control)
Age: 18e75 years
4 Weeks Increase in stool frequency (week 2 and week 4 [p < 0.0001],
week 3 [p ¼ 0.016])
Stool consistency and shape nearer normal parameters
(week 3 [p ¼ 0.0001], week 4 [p < 0.0001])
Reduction in frequency of abdominal symptoms (NS)
Improvement of AGACHAN score (p < 0.0001)
Yang et al., 200812 B. lactis DN-173010,
Yoghurt starters
S. thermophilus and
L. bulgaricus
RCT, parallel,
placebo-controlled
<3 Defecations/
week, hard stools,
non-organic and
habitual
constipation
Women (63 treatment:
63 control)
Age: 25e65 years
2 Weeks Increase in stool frequency: week 1 (p < 0.01) and week 2
(p < 0.01)
Improvement in defecation condition score (week 1
[p < 0.01] and week 2 [p < 0.01])
Improvement in stool consistency score after week 1
(p < 0.05) and week 2 (p < 0.01)
(b)
Bekkali
et al., 200723
B. biﬁdum, B. infantis,
B. longum, L. casei,
L. plantarum and
L. rhamnosus
Non-RCT, observational
pilot study
Rome III Children (20)
Age: 4e16 years
4 Weeks Increase in stool frequency in weeks 2 and 4
Decrease in number of faecal incontinence episodes
Hard stools (NS)
Abdominal pain decreased from 45% to 25% in week 2
and 20% at week 4.
Coccorullo et al., 201034 L. reuteri RCT, parallel,
placebo-controlled
Rome III Infants (22 treament:
22 control)
Age: 6 months
8 Weeks Higher stool frequency than placebo (week 2 [p ¼ 0.042],
week 4 [p ¼ 0.008] and week 8 [p ¼ 0.027])
Improvement in stool consistency but NS.
Inconsolable crying episodes (NS)
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In conclusion, this randomized, placebo-controlled trial sug-
gests that microbial cell preparation containing a mixture of
Lactobacillus and Biﬁdobacterium is effective in increasing stool
frequency and improving stool consistency. Furthermore, it could
reduce the symptoms of straining and sensation of incomplete
evacuation in adults with chronic functional constipation. There-
fore, microbial cell preparation may be used as an alternative
treatment for functional constipation.
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